DreganACharltonJChowienczykPet al.Chronic inflammatory disorders and risk of type 2 diabetes mellitus, coronary heart disease, and stroke: a population-based cohort study. Circulation2014; 130: 837–844.
2.
Sun HH and Tian F. Inflammatory bowel disease and cardiovascular disease incidence and mortality: a meta-analysis. Eur J Prev Cardiol 2018; 25: 1623–1631.
3.
FengWChenGCaiDet al.Inflammatory bowel disease and risk of ischemic heart disease: an updated meta-analysis of cohort studies. J Am Heart Assoc2017; 6. doi:10.1161/JAHA.
4.
BurischJMunkholmP. The epidemiology of inflammatory bowel disease. Scand J Gastroenterol2015; 50: 942–951.
5.
DuricovaDPedersenNElkjaerMet al.Overall and cause-specific mortality in Crohn’s disease: a meta-analysis of population-based studies. Inflamm Bowel Dis2010; 16: 347–353.
6.
RidkerPMEverettBMThurenTet al.Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med2017; 377: 1119–1131.
7.
LewisJDScottFIBrensingerCMet al.Increased mortality rates with prolonged corticosteroid therapy when compared with antitumor necrosis factor-alpha-directed therapy for inflammatory bowel disease. Am J Gastroenterol2018; 113: 405–417.
8.
WilleitPThompsonSGAgewallSet al.Inflammatory markers and extent and progression of early atherosclerosis: meta-analysis of individual-participant-data from 20 prospective studies of the PROG–IMT collaboration. Eur J Prev Cardiol2016; 23: 194–205.
9.
DreganA. Arterial stiffness association with chronic inflammatory disorders in the UK Biobank study. Heart2018; 104: 1257–1262.
10.
SagerHBKoenigW. Acute inflammation and long-term cardiovascular risk: identifying an unrecognised vulnerable gap. Eur J Prev Cardiol2017; 24: 1956–1957.
11.
HareDLToukhsatiSRJohanssonPet al.Depression and cardiovascular disease: a clinical review. Eur Heart J2014; 35: 1365–1372.
12.
UelandTLaugsandLEVattenLJet al.Extracellular matrix markers and risk of myocardial infarction: the HUNT Study in Norway. Eur J Prev Cardiol2017; 24: 1161–1167.
